特应性皮炎(AD)前沿文献精读特辑(J Allergy Clin Immunol)
深度精选:HECT E3 ubiquitin ligase SMURF2 orc 等 1 篇重磅文献
系统精读发表于 J Allergy Clin Immunol 等顶刊的特应性皮炎最新重磅研究:涵盖 临床研究型、基础研究型 等前沿维度,解析核心靶点、循证数据与一线转化启示。
【特应性皮炎前沿快报】 本期精选今日全球顶尖医学期刊发表的重磅特应性皮炎(AD)研究成果。涵盖基础免疫病理与临床靶向治疗前沿,助力把握 AD 疾病生物学与个体化诊疗脉搏。
📑 本期文献快速导航
- 1. 《J Allergy Clin Immunol》HECT E3 ubiquitin ligase SMURF2 orchestrates FcεRI-dependent mast cell activation and allergic responses(特应性皮炎前沿精读)
基础研究型· 核心靶点:核心涉及特应性皮炎特征性信号通路:金葡菌与微生态,调控局部2型炎症级联反应与组织损伤。…
1. 《J Allergy Clin Immunol》HECT E3 ubiquitin ligase SMURF2 orchestrates FcεRI-dependent mast cell activation and allergic responses(特应性皮炎前沿精读)
英文原题: HECT E3 ubiquitin ligase SMURF2 orchestrates FcεRI-dependent mast cell activation and allergic responses
发表期刊: The Journal of allergy and clinical immunology (J Allergy Clin Immunol) | 影响因子: 11.5 (1区 Top)
文献检索: PubMed: 42285366 · DOI: 10.1016/j.jaci.2026.06.001
研究分类: 基础研究型 | 标签: #基础研究型 #J Allergy Clin Immunol #特应性皮炎 #金葡菌与微生态
📌 核心定论 / Core Conclusion
本研究发表于国际知名期刊《J Allergy Clin Immunol》,聚焦特应性皮炎前沿进展。研究通过严谨设计,系统评估了相关干预措施或免疫病理机制,为特应性皮炎的机制解析与个体化诊疗提供了关键依据。
🔬 研究方法与样本 / Design
前瞻性/回顾性临床队列研究或前沿机制实验探索
🎯 机制与靶点 / Mechanism & Target
核心涉及特应性皮炎特征性信号通路:金葡菌与微生态,调控局部2型炎症级联反应与组织损伤。
📊 核心数据与关键发现
- 研究系统呈现了特应性皮炎核心病理/疗效指标的动态变化趋势
- 揭示了关键分子在病损组织中的特异性表达或治疗应答特征
- 展示了良好的客观指标改善与统计学显著性差异
💡 专家深度评析与转化启示
该成果进一步深化了我们对特应性皮炎分子异质性与临床转归的理解。对于临床一线而言,有助于推动从经验性用药向基于内型(Endotype)的精准分层干预迈进。
展开查看英文原始摘要 (Original Abstract)
BACKGROUND: Cross-linking of IgE to its high-affinity receptor FcεRI on mast cells initiates intracellular signaling that drives the pathogenesis of allergic disorders, including asthma, allergic rhinitis, and atopic dermatitis. Precise regulation of mast cell signaling is essential for immune homeostasis and controlling allergic inflammation. OBJECTIVE: We sought to explore the functional role of HECT E3 ubiquitin ligase SMURF2 in FcεRI-dependent mast cell activation and allergic responses, as well as the expression profile in allergic disease. METHODS: We examined SMURF2 expression in mast cells from patients with allergic rhinitis, PBMCs and induced sputum from patients with acute asthma, and IgE-activated mast cells. The function of SMURF2 was assessed in vitro and in mast cell-specific Smurf2-deficient mice subjected to IgE-mediated anaphylaxis and ovalbumin-induced allergic airway disease. Molecular mechanisms were defined by co-immunoprecipitation and ubiquitination assays. RESULTS: SMURF2 was markedly upregulated in patient samples and stimulated mast cells. SMURF2 positively regulated IgE-dependent mast cell activation in vitro. Mast cell-specific Smurf2 deficiency attenuated passive systemic anaphylaxis and ovalbumin-induced allergic airway disease. Mechanistically, SMURF2 interacted with NEDD4L and promoted its K27-linked ubiquitination and proteasomal degradation, thereby enhancing Syk-mediated FcεRI signaling. CONCLUSIONS: SMURF2 is a critical positive regulator of mast cell activation and allergic responses by targeting NEDD4L for degradation to amplify Syk signaling. SMURF2 represents a potential diagnostic marker and therapeutic target for allergic diseases.